Aytu Biopharma (AYTU) Receivables: 2015-2025
Historic Receivables for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to $33.2 million.
- Aytu Biopharma's Receivables rose 43.46% to $33.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.6 million, marking a year-over-year increase of 16.48%. This contributed to the annual value of $31.2 million for FY2025, which is 22.91% up from last year.
- According to the latest figures from Q3 2025, Aytu Biopharma's Receivables is $33.2 million, which was up 6.64% from $31.2 million recorded in Q2 2025.
- In the past 5 years, Aytu Biopharma's Receivables registered a high of $35.8 million during Q1 2025, and its lowest value of $21.6 million during Q3 2021.
- In the last 3 years, Aytu Biopharma's Receivables had a median value of $29.9 million in 2024 and averaged $29.9 million.
- As far as peak fluctuations go, Aytu Biopharma's Receivables surged by 438.72% in 2021, and later dropped by 22.55% in 2024.
- Aytu Biopharma's Receivables (Quarterly) stood at $23.0 million in 2021, then rose by 11.13% to $25.5 million in 2022, then rose by 15.09% to $29.4 million in 2023, then dropped by 13.60% to $25.4 million in 2024, then spiked by 43.46% to $33.2 million in 2025.
- Its Receivables was $33.2 million in Q3 2025, compared to $31.2 million in Q2 2025 and $35.8 million in Q1 2025.